


What is claimed is:

1. A pharmaceutical formulation comprising an enteric protectant and a compound of the formula:



5

wherein:

E₁ is -CO₂H, -CO₂R₅, -CO₂R_{5a}W₅ or -CO₂W₅;

G₁ is -N₃, -N(R₁₁)₂, -N(R₁₁)C(N(R₁₁))(N(R₁₁)₂), or -C(R₁₁)₂-N(R₁₁)₂;

T₁ is -NH(C(O)CH₃), -NH(C(O)CH₂F), -NH(C(O)CHF₂), or -

10 NH(C(O)CF₃);

U₁ is -OR₄, -SR₄, NHR₄ or N(R₄)₂;

R₁ is independently H or alkyl of 1 to 12 carbon atoms;

R₂ is independently R₃ or R₄ wherein each R₄ is independently substituted with 0 to 3 R₃ groups;

15 R₃ is independently F, Cl, Br, I, -CN, N₃, -NO₂, -OR_{6a}, -OR₁, -N(R₁)₂, -

N(R₁)(R_{6b}), -N(R_{6b})₂, -SR₁, -SR_{6a}, -S(O)R₁, -S(O)₂R₁, -S(O)OR₁, -S(O)OR_{6a}, -

S(O)₂OR₁, -S(O)₂OR_{6a}, -C(O)OR₁, -C(O)R_{6c}, -C(O)OR_{6a}, -OC(O)R₁, -

N(R₁)(C(O)R₁), -N(R_{6b})(C(O)R₁), -N(R₁)(C(O)OR₁), -N(R_{6b})(C(O)OR₁), -

C(O)N(R₁)₂, -C(O)N(R_{6b})(R₁), -C(O)N(R_{6b})₂, -C(NR₁)(N(R₁)₂), -

20 C(N(R_{6b}))(N(R₁)₂), -C(N(R₁))(N(R₁)(R_{6b})), -C(N(R_{6b}))(N(R₁)(R_{6b})), -

C(N(R₁))(N(R_{6b})₂), -C(N(R_{6b}))(N(R_{6b})₂), -N(R₁)C(N(R₁))(N(R₁)₂), -

N(R₁)C(N(R₁))(N(R₁)(R_{6b})), -N(R₁)C(N(R_{6b}))(N(R₁)₂), -

N(R_{6b})C(N(R₁))(N(R₁)₂), -N(R_{6b})C(N(R_{6b}))(N(R₁)₂), -

N(R_{6b})C(N(R₁))(N(R₁)(R_{6b})), -N(R₁)C(N(R_{6b}))(N(R₁)(R_{6b})), -

25 N(R₁)C(N(R₁))(N(R_{6b})₂), -N(R_{6b})C(N(R_{6b}))(N(R₁)(R_{6b})), -

N(R_{6b})C(N(R₁))(N(R_{6b})₂), -N(R₁)C(N(R_{6b}))(N(R_{6b})₂), -

N(R_{6b})C(N(R_{6b}))(N(R_{6b})₂), =O, =S, =N(R₁), or =N(R_{6b});

R₄ is independently alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12

carbon atoms, or alkynyl of 2 to 12 carbon atoms; and

R₅ is independently R₄ wherein each R₄ is substituted with 0 to 3 R₃ groups;

5 R_{5a} is independently alkylene of 1 to 12 carbon atoms, alkenylene of 2 to 12 carbon atoms, or alkynylene of 2-12 carbon atoms any one of which alkylene, alkenylene or alkynylene is substituted with 0-3 R₃ groups

R_{6a} is independently H or an ether- or ester-forming group;

R_{6b} is independently H, a protecting group for amino or the residue of a carboxyl-containing compound;

10 R_{6c} is independently H or the residue of an amino-containing compound;

W₅ is carbocycle or heterocycle wherein W₅ is independently substituted with 0 to 3 R₂ groups; and

R₁₁ is independently H or R₅.


15

2. The pharmaceutical formulation of claim 1 wherein E₁ is -CO₂R₅; G₁ is NH₂ or N₃; T₁ is NHC(O)CH₃; and U₁ is -OR₄.

3. The pharmaceutical formulation of claim 2 wherein E₁ is C(O)OCH₂CH₃; G₁ is NH₂; T₁ is NHC(O)CH₃; and U₁ is OCH(CH₂CH₃)₂.

20

4. The pharmaceutical formulation of claim 1 comprising a compound of the formula:




25

5. The pharmaceutical formulation of claim 4 wherein the

compound further comprises a phosphate salt.

6. The pharmaceutical formulation of claim 1 comprising a compound of the formula:



5

7. The pharmaceutical formulation of claim 1 wherein the enteric protectant is selected from cellulose acetate phthalate polymer, methyl acrylate-methacrylic acid copolymer, cellulose acetate succinate polymer, hydroxypropylmethylcellulose phthalate polymer, polyvinyl acetate phthalate polymer, cellulose acetate trimellitate polymer, hydroxypropyl methylcellulose phthalate succinate polymer, methacrylic acid polymer, and methacrylic acid ester polymer.

8. The pharmaceutical formulation of claim 1 wherein the formulation is a tablet.

9. The pharmaceutical formulation of claim 1 wherein the formulation is a capsule.

10. A pharmaceutical formulation comprising a liquid suspension of enteric coated particles of a compound of claim 1.

11. A method of inhibiting the activity of neuraminidase comprising the step of contacting a sample suspected of containing neuraminidase with a pharmaceutical formulation of claim 1.

12. The method of claim 11 wherein the neuraminidase is influenza neuraminidase *in vivo*.

13. A method for the treatment or prophylaxis of influenza infection
5 in a host comprising administering to the host a therapeutically effective amount of a pharmaceutical formulation of claim 1.